Press Releases Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
0.991 ^USD	-4.71%		-3.79%	-10.72%

Apr. 15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
Apr. 15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease	May. 21	AQ
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)	May. 14	AQ
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering	May. 08	AQ
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 16	AQ
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	Apr. 15	AQ
Organovo: Fiscal Q3 Earnings Snapshot	Feb. 08	AQ
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	Jan. 25	AQ
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	Jan. 09	AQ
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	Dec. 06	AQ
Organovo: Fiscal Q2 Earnings Snapshot	Nov. 10	AQ
Organovo Highlights FXR314 Combination Therapy Potential and Plan	Nov. 08	AQ
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	Nov. 03	PU
Organovo to Participate in the H.C. Wainwright Global Investment Conference	23-09-08	AQ
Organovo : Change in Certifying Accountants - Form 8-K	23-09-05	PU
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23	AQ
Organovo : Costs Associated with Exit/Disposal - Form 8-K	23-08-22	PU
Organovo Announces FXR Program	23-03-21	GL
ORGANOVO HOLDINGS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-03-15	AQ
ORGANOVO HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	23-02-09	AQ
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates	22-11-15	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Press Releases

Filters